Last Posted: Sep 10, 2018
- Poly (ADP-ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: A Drug Class Review.
Ringley J Tanner et al. P & T : a peer-reviewed journal for formulary management 2018 Sep (9) 549-556 - A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer.
de Souza Timoteo Ana Rafaela et al. Breast cancer research and treatment 2018 Aug - BRCA1 and BRCA2 Testing in Medically Underserved Medicare Beneficiaries With Breast or Ovarian Cancer.
Gross Amy L et al. JAMA 2018 Aug 320(6) 597-598 - Family History and Cancer
CDC Division of Cancer Control and Prevention, 2018 - Know Your Body. Know Your Family History.
Sun Hee Rim et al, CDC Blog, August 2018 - New Developments in Ovarian Cancer Treatment Are Showing Promise
A Park, Time, August 28, 2018 - Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort.
Li Jingmei et al. International journal of cancer 2018 Sep - Surgery for BRCA , TP53 and PALB2: a literature review.
Song Chin-Vern et al. Ecancermedicalscience 2018 12863 - Differences Among a Modern Cohort of BRCA Mutation Carriers Choosing Bilateral Prophylactic Mastectomies Compared to Breast Surveillance.
Gilbert Elizabeth et al. Annals of surgical oncology 2017 Oct 24(10) 3048-3054 - Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan.
Abdel-Razeq Hikmat et al. BMC cancer 2018 18(1) 152
.png)
No hay comentarios:
Publicar un comentario